Indirect comparison of Ixekizumab versus Guselkumab up to week 12

被引：0
|
作者：
Gottlieb, A. B. [1 ]
Ramot, Y. [2 ]
Smith, S. D. [3 ]
Saure, D. [4 ]
Schacht, A. [4 ]
Dossenbach, M. [4 ]
Wilhelm, S. [4 ]
Thaci, D. [5 ]
Eppendorfer, S. [6 ]
机构：
[1] Metropolitan Hosp New York, New York Med Coll, New York, NY USA
[2] Hadassah Hebrew Univ, Med Ctr, Jerusalem, Israel
[3] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[4] Eli Lilly & Co, Indianapolis, IN USA
[5] Univ Hosp Schleswig Holstein, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany
[6] Lilly Deutschland GmbH, Bad Homburg, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2019年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P108
引用
收藏
页码：120 / 120
页数：1
相关论文
共 50 条
  • [1] Indirect comparison of ixekizumab versus guselkumab up to week 12
    Gottlieb, A.
    Ramot, Y.
    Smith, S.
    Saure, D.
    Schacht, A.
    Dossenbach, M.
    Wilhelm, S.
    Thaci, D.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 90 - 90
  • [2] Indirect comparison of ixekizumab versus guselkumab up to week 12
    Gottlieb, A.
    Ramot, Y.
    Smith, S.
    Saure, D.
    Schacht, A.
    Dossenbach, M.
    Wilhelm, S.
    Thaci, D.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : S3 - S3
  • [3] Indirect comparison of ixekizumab versus risankizumab for up to 12 weeks of treatment in patients with moderate-to-severe psoriasis
    Gottlieb, Alice B.
    Ramot, Yuval
    Smith, Saxon D.
    Saure, Daniel
    Schuster, Christopher
    Schacht, Alexander
    Thaci, Diamant
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB226 - AB226
  • [4] Indirect comparison of ixekizumab versus tildrakizumab for up to 12 weeks of treatment in patients with moderate-to-severe psoriasis
    Gottlieb, Alice
    Saure, Daniel
    Wilhelm, Stefan
    Dossenbach, Martin
    Thaci, Diamant
    Smith, Saxon D.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB82 - AB82
  • [5] TILDRAKIZUMAB VERSUS GUSELKUMAB: A BUCHER INDIRECT COMPARISON
    Du Jardin, Gaarn K.
    Hurtado, P.
    Lange, M.
    McCool, R.
    Maeso Naval, S.
    Quickert, S.
    [J]. VALUE IN HEALTH, 2019, 22 : S597 - S597
  • [6] Ixekizumab versus guselkumab: 24-week clinical responses and 4-week gene expression data
    Blauvelt, A.
    Pinter, A.
    Tada, Y.
    Elmaraghy, H.
    Gallo, G.
    Nickoloff, B. J.
    Renda, L.
    Park, S.
    Guenther, L.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : B9 - B9
  • [7] Matching-adjusted indirect treatment comparison of guselkumab and ixekizumab in patients with moderate-to-severe psoriasis
    Varu, Abhishek
    Cameron, Chris
    Diels, Joris
    Hutton, Brian
    McElligott, Sean
    Schubert, Agata
    van Sanden, Suzy
    Villacorta, Reggie
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB187 - AB187
  • [8] Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison
    Ruggiero, Angelo
    Fabbrocini, Gabriella
    Cinelli, Eleonora
    Megna, Matteo
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (04) : 1028 - 1030
  • [9] Matching-Adjusted Indirect Comparison of the 52-Week Efficacy of Bimekizumab Versus Secukinumab and Ixekizumab for the Treatment of Radiographic Axial Spondyloarthritis
    Maksymowych, Walter P.
    Thom, Howard
    Morup, Michael F.
    Taieb, Vanessa
    Willems, Damon
    Lyris, Nikos
    Gaffney, Karl
    [J]. RHEUMATOLOGY AND THERAPY, 2024, 11 (04) : 1023 - 1041
  • [10] Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12
    Gottlieb, Alice B.
    Saure, Daniel
    Wilhelm, Stefan
    Dossenbach, Martin
    Schuster, Christopher
    Smith, Saxon D.
    Ramot, Yuval
    Thaci, Diamant
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (01) : 54 - 61
12345